Gain new KOL insights on the latest events that have the potential to shape the targeted treatment of Non-Small Cell Lung Cancer (NSCLC). Topics covered include opinions about Tagrisso (osimertinib; AstraZeneca) as a newly approved second-line treatment for EGFR T790M mutation-positive NSCLC, the approval of Portrazza (necitumumab; Eli Lilly) for first-line squamous NSCLC therapy, and the expansion of the label for Xalkori (crizotinib; Pfizer) to include the first-line treatment of patients in the EU with ALK-positive NSCLC and patients in the US with ROS1-positive advanced NSCLC. KOLs also discuss Alecensa (alectinib; Roche) following its approval as a second-line treatment for ALK-positive metastatic NSCLC, and assess topline KEYNOTE-010 trial data for Keytruda (pembrolizumab; Merck & Co.) in the second-line treatment of PD-L1 positive advanced NSCLC.
Key Questions Answered in this Update Bulletin:
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Table of Contents
for Non-Small Cell Lung Cancer: Update Bulletin [Jan 2016]
|Title||Date Published||Price from||More Details|
|Physician Views: Is the HER2-positive breast cancer extended adjuvant opportunity big enough to support neratinib's blockbuster forecasts?|
Scope Top-line data from the ExteNET study – which were released earlier this week – appear to estab...
|28 Jul 2014 by FirstWord Pharma||USD $695||More Info|
|Physician Views: Avastin to lose share as front-line therapy for first-line metastatic colorectal cancer?|
Scope Two recent developments appear poised to shift the typical US-based treatment regimen for firs...
|13 Jul 2014 by FirstWord Pharma||USD $695||More Info|
|The Future of Cancer Immunotherapy: KOL Views Bring Opportunities into Sharp Focus|
IntroductionThere has been considerable media hype and clinical interest in cancer immunotherapy in ...
|01 Jul 2014 by FirstWord Pharma||USD $4,995||More Info|
|Physician Views: Expanded access in cancer – how are oncologists utilising this opportunity?|
Scope According to analysts at Barclays, oncology continues to attract around one-third of pharma's ...
|28 Apr 2014 by FirstWord Pharma||USD $695||More Info|
|Breast Cancer: New targeted therapies transform treatment - KOL Insight|
IntroductionThe introduction of targeted therapies revolutionised the breast cancer market, widening...
|10 Feb 2014 by FirstWord Pharma||USD $7,900||More Info|
|Physician Views: Bayer's M&A catalyst – is Xofigo a paradigm shifter for the prostate cancer market?|
Scope Already positioned as one of the most commercially promising new drug approvals of 2013, Alget...
|01 Dec 2013 by FirstWord Pharma||USD $695||More Info|
|KOL Insight: Prostate Cancer: Competition intensifies in race to the top|
IntroductionThe Prostate Cancer market has seen a number of progressive changes in recent years. The...
|01 Nov 2013 by FirstWord Pharma||USD $7,900||More Info|
|Consensus Outlook: Prostate Cancer- Competition intensifies in race to the top|
IntroductionCharting the Future Prostate Cancer Market LandscapeThe prostate cancer market has exper...
|01 Nov 2013 by FirstWord Pharma||USD $4,995||More Info|
|Colorectal Cancer -- KOL Insight Module|
IntroductionThe global market for colorectal cancer (CRC) drugs is undergoing a fundamental shift du...
|01 Oct 2013 by FirstWord Pharma||USD $7,900||More Info|
|Physician Views: What is reaction among urologists, oncologists to the Xtandi PREVAIL data – can it displace Zytiga in the pre-chemotherapy prostate cancer setting?|
ScopeThe prostate cancer market looks poised to enter its next stage of evolution in 2014, with Medi...
|01 Oct 2013 by FirstWord Pharma||USD $695||More Info|
This report is published by FirstWord Pharma
Download Free Report Summary PDF
Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.
Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.
Accepted Card Types
Buy now using our secure payment system.